Imaging and modulating antisense microdistribution in solid human xenograft tumor models

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5935-5941

  Mocanu, Joseph D ^a,b   Yip, Kenneth W ^a,b   Skliarenko, Julia ^a   Shi, Wei ^a   Busson, Pierre ^c   Lo, Kwok Wai ^d   Bastianutto, Carlo ^a   Liu, Fei Fei ^a,b,e  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FLUORESCEIN; HOE 33342; N ACETYLCOLCHINOL PHOSPHATE; PHOSPHOROTHIOIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HYPOXIA; IMMUNE DEFICIENCY; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SOLID TUMOR; STEREOMICROSCOPY; TUMOR NECROSIS; TUMOR VASCULARIZATION; XENOGRAFT;

ALGORITHMS; ANIMALS; ANOXIA; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DIAGNOSTIC IMAGING; HUMANS; MICE; MICE, SCID; NECROSIS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; ORGANOPHOSPHORUS COMPOUNDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35348909784     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-3085     Document Type: Article

References (25)

1. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
2. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997;3:177-82.
3. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-46.
4. Jain RK. Delivery of molecular and cellular-medicine to solid tumors. Adv Drug Deliv Rev 2001;46:149-68.
5. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
6. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49.
7. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
8. Milosevic MF, Fyles AW, Wong R, et al. Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 1998;82:2418-26.
9. Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res 2006;66:2074-80.
10. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer 2005;5:468-79.
11. Crooke ST. Progress in antisense technology. Annu Rev Med 2004;55:61-95.
12. Yip KW, Mocanu JD, Au PY, et al. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res 2005;11:8131-44.
13. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8:1974-83.
14. Micheletti G, Poli M, Borsotti P, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003;63:1534-7.
15. Cheung ST, Huang DP, Hui AB, et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999;83:121-6.
16. Busson P, Ganem G, Flores P, et al. Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 1988;42:599-606.
17. Evans SM, Hahn S, Pook DR, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 2000;60:2018-24.
18. Trotter MJ, Chaplin DJ, Durand RE, Olive PL. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int J Radiat Oncol Biol Phys 1989;16:931-4.
19. Gleave M, Tolcher A, Miyake H, et al. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-8.
20. Benimetskaya L, Wittenberger T, Stein CA, et al. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-β and -γ. Clin Cancer Res 2004;10:3678-88.
21. Wang J, Chen P, Mrkobrada M, Hu M, Vallis KA, Reilly RM. Antisense imaging of epidermal growth factor-induced p21WAF-1/CIP-1 gene expression in MDA-MB-468 human breast cancer xenografts. Eur J Nucl Med Mol Imaging 2003;30:1273-80.
22. Huxham LA, Kyle AH, Baker JHE, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 2004;64:6537-41.
23. Lankelma J, Dekker H, Fernandez Luque R, et al. Doxorubicin gradients in human breast cancer. Clin Cancer Res 1999;5:1703-7.
24. Pietras K, Rubin K, Sjoblom T, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-84.
25. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.